305350-87-2 Usage
Description
SL 327 is a dual specific threonine/tyrosine kinase inhibitor that targets MEK1 and MEK2, which are key components of the RAS/RAF/MEK/ERK signaling pathway. This pathway regulates various cellular processes, and SL 327 has been shown to inhibit ERK1, MKK/p38, MKK4, JNK, and PKC at higher concentrations. Notably, SL 327 can rapidly pass the blood-brain barrier, making it a valuable tool for studying the effects of RAS/RAF/MEK/ERK signaling pathway inhibition on behavior and cognitive functions.
Uses
Used in Pharmaceutical Industry:
SL 327 is used as a selective inhibitor of MEK1 and MEK2 for targeting the RAS/RAF/MEK/ERK signaling pathway in the development of potential therapeutic agents.
Used in Neuroscience Research:
SL 327 is used as a research tool to dissect the effects of RAS/RAF/MEK/ERK signaling pathway inhibition on various aspects of behavior and cognitive functions, such as long-term memory, spatial learning, and fear/operant conditioning.
Biological Activity
Selective inhibitor of MEK1 and MEK2 (IC 50 values are 0.18 and 0.22 μ M respectively); blocks hippocampal LTP in vitro . Brain penetrant in vivo , blocking fear conditioning and learning in rats, and producing neuroprotection in mice, following systemic administration.
Biochem/physiol Actions
SL327 is a selective MEK1/2inhibitor (IC50 values are 0.18 and 0.22 μM for MEK1 and MEK2 respectively), which blocks hippocampal LTP in vitro. SL327 is a brain penetrant in vivo blocking fear conditioning and learning in rats, and producing neuroprotection in mice following systemic administration.
Check Digit Verification of cas no
The CAS Registry Mumber 305350-87-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,5,3,5 and 0 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 305350-87:
(8*3)+(7*0)+(6*5)+(5*3)+(4*5)+(3*0)+(2*8)+(1*7)=112
112 % 10 = 2
So 305350-87-2 is a valid CAS Registry Number.
InChI:InChI=1/C16H12F3N3S/c17-16(18,19)14-4-2-1-3-12(14)13(9-20)15(22)23-11-7-5-10(21)6-8-11/h1-8H,21-22H2/b15-13+
305350-87-2Relevant articles and documents
α-[Amino(4-aminophenyl)thio]methylene-2-(trifluoromethyl)benzeneacetonitrile; Configurational equilibria in solution
McElhinny, Charles J.,Lewin, Anita H.,Brieaddy, Larry,Fix, Scott,Imler, Gregory H.,Deschamps, Jeffrey,Mascarella, S. Wayne,Seltzman, Herbert H.,Anantha Reddy,Carroll, F. Ivy
, (2021)
Inconsistent results have been reported for the effects of the mitogen-activating extracellular kinase (MEK) inhibitor α-[amino(4-aminophenyl)thio]methylene-2-(trifluoromethyl)benzeneacetonitrile (SL 327) on ethanol-induced conditioned place preference (EtOH-CPP). Since such inconsistencies may be due to the configurational composition of administered SL 327, the interconvertibility of the geometric isomers of this class of compounds has been investigated. This study provides conditions for determination of configurational composition of this class of compounds by HPLC and by 1H NMR and reports details of configurational equilibria as a function of medium and time in solution along with solubility data for SL 327 in aqueous DMSO. The results suggest that the apparently inconsistent results reported for CPP-EtOH may be due to the administration of suspension vs. solutions, as well as to different configurational compositions of SL 327.
Methods for treating seizure disorders by inhibiting MAPK pathway activation
-
, (2008/06/13)
Excessive brain neuronal excitability, associated with a seizure disorder, can be correlated with increased mitogen-activated protein kinase (MAPK) activity in neurons. Such excessive excitability can be ameliorated by administering an effective amount of
